drugset
drugset / Trial / NCT05972044

A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)

NCT05972044 ↗

Phase 3 Completed 516 enrolled Axsome Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with ADHD.

Timeline

Start
2023-07-06
Primary completion
2025-02-07
Completion
2025-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Solriamfetol Small molecule 150 mg —
Subject Solriamfetol Small molecule 300 mg —

Indications

attention deficit-hyperactivity disorder